

Electronically Filed on October 19, 2009

Customer No.: 20462
Confirmation No. 4857

Attorney Docket No. P33159USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sehmi et al. Date: October 19, 2009
Serial No.: 10/539,385 Group Art Unit No.: 1624
Filed: June 16, 2005 Examiner: B.L. Coleman
For: Benzazepine Derivatives for the Treatment of Neurological Disorders

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FILING OF A SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



Duke M. Fitch
Agent for Applicants
Registration No. 63,058

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5023
Facsimile (610) 270-5090